Jill Feldman: New treatments for lung cancer are critical, but they aren’t enough
Jill Feldman, the Co-Founder EGFR Resisters, shared a post on X by CURE Today, adding:
“New treatments for lung cancer are critical, but they aren’t enough. We can’t keep kicking the can down the road, only looking for the next drug when we still don’t fully understand the link between genetics and lung cancer. We need to understand WHY lung cancer develops, WHAT drives resistance, and HOW to catch it before it spreads.
Why does this study give us the best shot at answering those questions? One of the biggest barriers in lung cancer (all cancer) research is the mountains of rich data out there that aren’t being used to its potential because it’s fragmented and trapped in silos. This study eliminates those barriers. It’s a true partnership in which advocates and community leaders have a direct say in how the data is used to drive meaningful research. Balancing Hope and urgency is not easy – this is the only way to move research forward quickly and meaningfully.
Thank you, CURE Today, for sharing my article.”
Quoting CURE Today’s post below:
“The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of Lung Cancer.
Read more from my Jill Feldman and the study below.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023